Pasar al contenido principal

FRAGMENTOS DE LOS TRNAS COMO MEDIADORES DE LOS PROCESOS NEURODEGENERATIVOS: IMPLICACIONES EN LA ENFERMEDAD DE HUNTINGTON

PID2020-113953RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Small RNAs in plasma extracellular vesicles define biomarkers of premanifest changes in Huntington's disease

  • Herrero-Lorenzo, Marina|||0000-0003-2693-0700
  • Pérez Pérez, Jesús|||0000-0002-9835-0484
  • Escaramís, G.
  • Martínez-Horta, Saul|||0000-0003-0125-7249
  • Pérez-González, R.
  • Rivas-Asensio, E.
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Gámez-Valero, A.
  • Martí, Eulàlia|||0000-0002-1030-3158
Despite the advances in the understanding of Huntington's disease (HD), there is a need for molecular biomarkers to categorize mutation carriers during the preclinical stage of the disease preceding functional decline. Small RNAs (sRNAs) are a promising source of biomarkers since their expression levels are highly sensitive to pathobiological processes. Here, using an optimized method for plasma extracellular vesicles (EVs) purification and an exhaustive analysis pipeline of sRNA sequencing data, we show that EV-sRNAs are downregulated early in mutation carriers and that this deregulation is associated with premanifest cognitive performance. Seven candidate sRNAs (tRF-Glu-CTC, tRF-Gly-GCC, miR-451a, miR-21-5p, miR-26a-5p, miR-27a-3p and let7a-5p) were validated in additional subjects, showing a significant diagnostic accuracy at premanifest stages. Of these, miR-21-5p was significantly decreased over time in a longitudinal study; and miR-21-5p and miR-26a-5p levels correlated with cognitive changes in the premanifest cohort. In summary, the present results suggest that deregulated plasma EV-sRNAs define an early biosignature in mutation carriers with specific species highlighting the progression and cognitive changes occurring at the premanifest stage.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Small RNAs in plasma extracellular vesicles define biomarkers of premanifest changes in Huntington's disease

  • Herrero-Lorenzo, Marina
  • Perez-Perez, Jesús
  • Escaramís, Georgia
  • Martinez-Horta, Saul
  • Pérez-González, Rocío
  • Rivas-Asensio, Elisa
  • Kulisevsky, Jaime
  • Gámez-Valero, Ana
  • Martí, Eulàlia
Despite the advances in the understanding of Huntington's disease (HD), there is a need for molecular biomarkers to categorize mutation carriers during the preclinical stage of the disease preceding functional decline. Small RNAs (sRNAs) are a promising source of biomarkers since their expression levels are highly sensitive to pathobiological processes. Here, using an optimized method for plasma extracellular vesicles (EVs) purification and an exhaustive analysis pipeline of sRNA sequencing data, we show that EV-sRNAs are downregulated early in mutation carriers and that this deregulation is associated with premanifest cognitive performance. Seven candidate sRNAs (tRF-Glu-CTC, tRF-Gly-GCC, miR-451a, miR-21-5p, miR-26a-5p, miR-27a-3p and let7a-5p) were validated in additional subjects, showing a significant diagnostic accuracy at premanifest stages. Of these, miR-21-5p was significantly decreased over time in a longitudinal study; and miR-21-5p and miR-26a-5p levels correlated with cognitive changes in the premanifest cohort. In summary, the present results suggest that deregulated plasma EV-sRNAs define an early biosignature in mutation carriers with specific species highlighting the progression and cognitive changes occurring at the premanifest stage., This work was supported by the Spanish government through the grant PID2020-113953RB-I00 funded by the Spanish Ministry of Science and Innovation/Spanish State Research Agency (10.13039/501100011033). The study was also supported by a 2021 Human Biology Project from the Huntington's Disease Society of America (HDSA) granted to Ana Gámez-Valero. Ana Gámez-Valero postdoctoral contract was also supported by the 2019 Juan de la Cierva fellowship FJC2019-039633-I. The PhD contract of Marina Herrero-Lorenzo was supported by a fellowship from the Spanish Ministry of Science and Innovation., Peer reviewed
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

RTP801 interacts with the tRNA ligase complex and dysregulates its RNA ligase activity in Alzheimer's disease

  • Campoy-Campos, Genís
  • Solana-Balaguer, Júlia
  • Guisado-Corcoll, Anna
  • Chicote-González, Almudena
  • García-Segura, Pol
  • Pérez-Sisqués, Leticia
  • Gabriel Torres, Adrián
  • Canal, Mercè
  • Molina-Porcel, Laura
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
  • Pouplana, Lluís Ribas de
  • Alberch, Jordi
  • Martí, Eulàlia
  • Giralt, Albert
  • Pérez-Navarro, Esther
  • Malagelada, Cristina
RTP801/REDD1 is a stress-responsive protein overexpressed in neurodegenerative diseases such as Alzheimer's disease (AD) that contributes to cognitive deficits and neuroinflammation. Here, we found that RTP801 interacts with HSPC117, DDX1 and CGI-99, three members of the tRNA ligase complex (tRNA-LC), which ligates the excised exons of intron-containing tRNAs and the mRNA exons of the transcription factor XBP1 during the unfolded protein response (UPR). We also found that RTP801 modulates the mRNA ligase activity of the complex in vitro since RTP801 knockdown promoted XBP1 splicing and the expression of its transcriptional target, SEC24D. Conversely, RTP801 overexpression inhibited the splicing of XBP1. Similarly, in human AD postmortem hippocampal samples, where RTP801 is upregulated, we found that XBP1 splicing was dramatically decreased. In the 5xFAD mouse model of AD, silencing RTP801 expression in hippocampal neurons promoted Xbp1 splicing and prevented the accumulation of intron-containing pre-tRNAs. Finally, the tRNA-enriched fraction obtained from 5xFAD mice promoted abnormal dendritic arborization in cultured hippocampal neurons, and RTP801 silencing in the source neurons prevented this phenotype. Altogether, these results show that elevated RTP801 impairs RNA processing in vitro and in vivo in the context of AD and suggest that RTP801 inhibition could be a promising therapeutic approach., This work was supported in part by the grants SAF2017-88812-R and PID2020-119236RB-I00 by MICIU/AEI/10.13039/501100011033 and by 'ERDF A way of making Europe' (from CM), PID2020-119386RB-I00 (from JA), PID2019-106447RB-I00 (from EP-N), PID2020- 113953RB-I00 (from EM), and PID2019-110356RB-I00 (from JF-I and ES).